Readoutin 14d
Clarity Pharmaceuticals Ltd — 64Cu-SAR-bisPSMA
Phase 3 primary completion: 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Prostate Cancer